ATE114116T1 - Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel. - Google Patents

Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel.

Info

Publication number
ATE114116T1
ATE114116T1 AT87902913T AT87902913T ATE114116T1 AT E114116 T1 ATE114116 T1 AT E114116T1 AT 87902913 T AT87902913 T AT 87902913T AT 87902913 T AT87902913 T AT 87902913T AT E114116 T1 ATE114116 T1 AT E114116T1
Authority
AT
Austria
Prior art keywords
administration
lhrh
combination
steroid
hormone
Prior art date
Application number
AT87902913T
Other languages
English (en)
Inventor
William F Crowley Jr
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25287892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE114116(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE114116T1 publication Critical patent/ATE114116T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AT87902913T 1986-03-21 1987-03-20 Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel. ATE114116T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/842,643 US4762717A (en) 1986-03-21 1986-03-21 Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive

Publications (1)

Publication Number Publication Date
ATE114116T1 true ATE114116T1 (de) 1994-12-15

Family

ID=25287892

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87902913T ATE114116T1 (de) 1986-03-21 1987-03-20 Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel.

Country Status (7)

Country Link
US (1) US4762717A (de)
EP (1) EP0298990B1 (de)
JP (1) JP2703243B2 (de)
AT (1) ATE114116T1 (de)
CA (1) CA1339345C (de)
DE (1) DE3750764T2 (de)
WO (1) WO1987005514A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116818A (en) * 1987-03-10 1992-05-26 Medical College Of Hampton Roads Method and kit for contraception with GnRH-antagonist
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US6489288B1 (en) 1990-03-16 2002-12-03 Applied Research Systems Ars Holding Treatment of polycystic ovarian disease
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5494899A (en) * 1993-04-07 1996-02-27 Oklahoma Medical Research Foundation Selective regulation of B lymphocyte precursors by hormones
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
US7989436B2 (en) * 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
WO2002002144A1 (fr) * 2000-07-05 2002-01-10 Takeda Chemical Industries, Ltd. Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles
DE60217324T2 (de) * 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
EP1260225A1 (de) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. Pharmazeutische Zusammensetzung für die Hormonersatztherapie
DK1390042T3 (da) * 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
DE60234515D1 (de) * 2001-05-23 2010-01-07 Pantarhei Bioscience Bv Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
DE60216630T2 (de) * 2001-11-15 2007-09-20 Pantarhei Bioscience B.V. Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
NZ591627A (en) * 2001-12-05 2012-09-28 Teva Womens Health Inc Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20030144203A1 (en) * 2001-12-19 2003-07-31 Voyager Pharmaceutical Corporation Methods for slowing senescence and treating and preventing diseases associated with senescence
AU2002366800B2 (en) * 2001-12-20 2006-08-03 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
SI1511496T1 (sl) * 2002-06-11 2007-04-30 Pantarhei Bioscience Bv Metoda zdravljenja ali prevencije imunsko mediiranih motenj in farmacevtska formulacija za njeno uporabo
ES2399423T3 (es) * 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
EP1526856B1 (de) * 2002-07-12 2008-01-02 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US7812010B2 (en) * 2003-01-02 2010-10-12 Femmepharma, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
MXPA05010871A (es) * 2003-04-11 2005-11-25 Barr Lab Inc Metodos para administrar estrogenos y progestinas.
JP4898431B2 (ja) * 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
PL1624878T3 (pl) * 2003-05-22 2007-01-31 Pantarhei Bioscience Bv Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu
CA2771944A1 (en) * 2003-07-16 2005-01-27 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
AU2004277998A1 (en) * 2003-10-01 2005-04-14 Janssen Pharmaceutica N.V. Extended triphasic contraceptive regimens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2104489A2 (de) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topische verabreichung von danazol
DE602008001783D1 (de) * 2007-01-08 2010-08-26 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2782584B1 (de) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und -therapien
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US12661321B2 (en) 2017-06-30 2026-06-23 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
US11376220B2 (en) 2017-06-30 2022-07-05 Therio, LLC Single-injection methods and formulations to induce and control multiple ovarian follicles in bovine, caprine, ovine, camelid and other female animals
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
EP4719422A1 (de) 2023-05-26 2026-04-08 Pandora Endocrine Innovation B.V. Progestogenfreie orale dosiereinheit zur verwendung bei der weiblichen empfängnisverhütung und behandlung von endometriose

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US393924A (en) * 1888-12-04 D q proctor
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3822355A (en) * 1971-12-10 1974-07-02 Biolog Concepts Inc Novel oral contraceptive method
US3836651A (en) * 1972-02-22 1974-09-17 Biolog Concepts Inc Novel oral contraceptive combination
US3969502A (en) * 1972-04-14 1976-07-13 Schering Aktiengesellschaft Method for contraception by the administration of sequential contraceptive preparations
DE2310963A1 (de) * 1972-04-14 1974-09-05 Schering Ag Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
US3932635A (en) * 1972-04-24 1976-01-13 Syntex Corporation Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
US3942641A (en) * 1972-05-05 1976-03-09 Syntex Corporation Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
CS180644B2 (en) * 1973-09-29 1978-01-31 Takeda Chemical Industries Ltd Process for preparing nonapeptides
US4083967A (en) * 1973-11-01 1978-04-11 Burroughs Wellcome Co. Nona- and decapeptides
US4072668A (en) * 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
DE2365103C3 (de) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen V erwendung von Hormonen zur Kontrazeption
JPS50142563A (de) * 1974-04-26 1975-11-17
IL48277A (en) * 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4338305A (en) * 1975-03-24 1982-07-06 American Home Products Corporation Use of LRH and LRH agonists
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4010256A (en) * 1975-07-30 1977-03-01 Professional Staff Association Of The Los Angeles County Harbor General Hospital Male contraceptive and method of achieving male contraception
JPS6047248B2 (ja) * 1975-10-21 1985-10-21 三共株式会社 畜産用黄体形成ホルモン分泌促進法
US4089946A (en) * 1976-06-07 1978-05-16 American Home Products Corporation Claudogenic-interceptive nonapeptides
US4143136A (en) * 1976-11-20 1979-03-06 Akzona Incorporated Method of contraception
US4218439A (en) * 1977-07-14 1980-08-19 The Salk Institute For Biological Studies Peptide which inhibits gonadal function
DE2735515A1 (de) * 1977-08-06 1979-02-22 Hoechst Ag Verwendung von lh-rh-peptiden als antikonzeptive
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4377515A (en) * 1979-10-01 1983-03-22 Merck & Co., Inc. Long lasting agonists and antagonists of LH-RH
US4493934A (en) * 1979-10-01 1985-01-15 Merck & Co., Inc. 2(3-Amino-2-oxopyrrolidin-1-yl) acetic acid and n-acylated derivatives thereof
US4315925A (en) * 1980-05-30 1982-02-16 University Of Kentucky Research Foundation Method of administering natural female sex hormones
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
US4419347A (en) * 1980-10-06 1983-12-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
JPS5913731A (ja) * 1982-07-07 1984-01-24 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 黄体形成ホルモン放出性因子主働薬を用いる受胎抑制
CS230614B1 (en) * 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4504414A (en) * 1983-03-28 1985-03-12 Board Of Regents, The University Of Texas System Synthetic pyridyl-alanyl decapeptides having antiovulatory activity
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer

Also Published As

Publication number Publication date
JPH01502265A (ja) 1989-08-10
DE3750764D1 (de) 1994-12-22
US4762717A (en) 1988-08-09
EP0298990A4 (de) 1989-11-07
DE3750764T2 (de) 1995-06-29
EP0298990A1 (de) 1989-01-18
JP2703243B2 (ja) 1998-01-26
EP0298990B1 (de) 1994-11-17
CA1339345C (en) 1997-08-26
WO1987005514A1 (en) 1987-09-24

Similar Documents

Publication Publication Date Title
DE3750764D1 (de) Kontinuierliche verabreichung des luteinisierendes hormon abgebenden hormons in kombination mit sexsteroidverabreichung als empfängnisverhütungsmittel.
DK351887D0 (da) Kombinationsdosisform til hormonbehandling og kontraception for kvinder i praemenopausen
US4066757A (en) Oral contraceptive regimen
BR8807426A (pt) Composicoes e metodos contraceptivos e controle do cancer de mama
ZA897977B (en) Contraception system and method
US3755573A (en) Fertility control empoying quinestrol and quingestanol acetate
Corbin et al. Post-coital contraceptive and uterotrophic effects of luteinizing hormone releasing hormone
CUNNINGHAM et al. The mechanism of ovulation inhibition by triamcinolone acetonide
Ulmann Uses of RU 486 for contragestion: an update
Check et al. Ovulation induction and pregnancy with an estrogen-gonadotropin stimulation technique in a menopausal woman with marked hypoplastic ovaries
US4010261A (en) Method to prevent reproduction with [Des-Gly]10 -GN-RH nonadeptide amide analogs in position
GB1253500A (en) Method of contraception
Jaramillo et al. Clinical studies with D-Trp6-luteinizing hormone-releasing hormone in anovulatory women
GB1214712A (en) Contraceptive preparations
Carlström et al. Serum Levels of FSH, LH, Estradiol-17β and Progesterone following the Administration of a Combined Oral Contraceptive Containing 20 μg Ethinylestradiol
Senior Drugs used in menopausal disorders
GB1312760A (en) Method of contraception
陆仁康 et al. Inhibition of Ovulation in Women by Intranasal Treatment with Luteinizing Hormone Releasing Hormone Agonist
YOSHIDA et al. Effect of Sex Steroid Hormones on the Serum Prolactin Concentration
Crist Post-coital estrogen
Kabiraj et al. Effects of hysterectomy, administration of uterine extract, posterior pituitary extract and aspirin on the length of pseudopregnancy in rats

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee